On January 11, 2026, Argo Biopharmaceutical Co., Ltd. revealed from Shanghai and Boston its plans for advancing siRNA therapies, with Dr. Dongxu Shu, a Co-Founder, Chairman of the Board, and CEO, leading the efforts. Argo Biopharma is a clinical-stage biotechnology company dedicated to developing innovative siRNA treatments for various conditions.